NRC-2694 dihydrochloride | 1172627-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: NRC-2694 dihydrochloride
• 英文别名: N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;dihydrochloride
• CAS: 1172627-00-7
• 化学式: C24H28Cl2N4O3
• 分子量: 491.4
• InChiKey: HHXJUNYMDONXMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.31
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  68.7
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE<br/>[FR] PROCÉDÉ AMÉLIORÉ POUR LA PRÉPARATION DE DICHLORHYDRATE DE N-(3-ÉTHYNYLPHÉNYL)-7-MÉTHOXY-6-(3-MORPHOLINOPROPOXY)QUINAZOLIN-4-AMINE
  申请人：NATCO PHARMA LTD

  公开号：WO2018189747A1

  公开（公告）日：2018-10-18

  Present invention relates to an improved process for the preparation of N-(3- ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.

  本发明涉及一种改进的制备N-(3-乙炔基苯基)-7-甲氧基-6-(3-吗啉基丙氧基)喹唑啉-4-胺二盐酸盐的方法。
• Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride
  申请人：NATCO PHARMA LIMITED

  公开号：US11091470B2

  公开（公告）日：2021-08-17

  Present invention relates to an improved process for the preparation of N—(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.

  本发明涉及一种制备式-I的N-(3-乙炔基苯基)-7-甲氧基-6-(3-吗啉丙氧基)喹唑啉-4-胺二盐酸盐的改进工艺。
• AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE
  申请人：Natco Pharma Limited

  公开号：EP3609875B1

  公开（公告）日：2021-10-20
• AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE
  申请人：NATCO PHARMA LIMITED

  公开号：US20200331899A1

  公开（公告）日：2020-10-22

  Present invention relates to an improved process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.
• [EN] EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER<br/>[FR] INHIBITEUR D'EGFR POUR LE TRAITEMENT DU CANCER DE LA TÊTE ET DU COU
  申请人：[en]NATCO PHARMA LIMITED

  公开号：WO2022258977A1

  公开（公告）日：2022-12-15

  The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3- morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The invention also relates to the treatment of head and neck cancer with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl- propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof, wherein the treating the head and neck cancer comprises reducing the size of one or more tumours associated with the head and neck cancer.